Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
|Articles|March 14, 2008
AstraZeneca to provide more information about its U.S. business
AstraZeneca will share more information about its U.S. business
Advertisement
AstraZeneca announced that its U.S. business will publicly share additional or enhanced
To see more Daily News articles,
To go to the Drug Topics homepage,
Advertisement
Related to this article
The update adds efficacy and safety data on adults newly diagnosed with pulmonary arterial hypertension.
Mark Garofoli, PharmD, BCGP, CPE, CTTS, explains how to guide patients past crowded combination products, uncertain decongestants, and hidden risks in OTC aisles.
Chad Worz, PharmD, BCGP, FASCP, explains why the Main Street Pharmacy Access Act's reimbursement provisions are key to unlocking pharmacy's clinical future.
Cohort studies found no clear cardiovascular benefit from PPV23 vaccination, leaving its role in cardiovascular prevention unresolved.
A high-dose flu vaccine lowered flu- and pneumonia-related hospital stays in patients with chronic lung disease, reinforcing flu and pneumococcal vaccinations.
In a review of records assessing patients with type 2 diabetes, researchers provide a comprehensive detail of strategies leading to diabetes remission though gaps persist.
A guide built from conversations with pharmacists on social media and independent pharmacy owners.
Advertisement
Advertisement
Trending on Drug Topics
1
GLP-1 Therapy Must Prioritize Metabolic Quality Over Weight Loss
2
FDA Approves Update for Winrevair Based on Phase 3 HYPERION Trial Data
3
PPV23 Vaccination Found to Not Reduce Cardiovascular Risk
4
COVID-19 Vaccine Hesitancy in 2026: How Attitudes Have Shifted
5